MediMabBio has been selected for the Global Marketing Support Program for Pharmaceutical and Biotechnology Companies, one of the key initiatives under the K-VIP (Korea BioHealth Value-up Innovation Program) organized by the Korea Health Industry Development Institute (KHIDI).
The program supports innovative Korean biopharmaceutical companies in expanding their global presence by enhancing international marketing activities, strengthening global networks, and identifying strategic business partners. Through this initiative, MediMabBio will further accelerate its global business development efforts, including participation in international conferences and partnering events, promotion of its proprietary technology platforms and pipeline assets, and engagement with potential licensing partners worldwide.
MediMabBio remains committed to advancing innovative antibody and cytokine-based therapeutics for cancer and autoimmune diseases and to expanding global partnership opportunities that will accelerate the development and commercialization of its pipeline.